SCHEMBL12601802

SCHEMBL12601802

O=C(CCc1ccc(O)cc1)CC(=O)CCc1ccc(O)c(O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 3/20 0.65
ALOX15 P16050 3/20 0.62
IGF1R P08069 2/20 0.62
ALOX5 P09917 1/20 0.58
OR51E2 Q9H255 1/20 0.58
CYP19A1 P11511 2/20 0.57
TYR P14679 1/20 0.57
CCR5 P51681 3/20 0.56
APP P05067 1/20 0.53
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
SLC16A3 O15427 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
TTR P02766 1/20 0.51
ESR1 P03372 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21203290 0.93 IAPP (0.72) IAPPALOX15IGF1RALOX5CYP19A1
Didemethyltetrahydrocurcumin SCHEMBL6344877 0.93 IAPP (0.73) IAPPALOX15IGF1RALOX5OR51E2
Letestuianin C SCHEMBL4410123 0.87 F2RL1 (0.60) ALOX5OR51E2CYP19A1KDM4EMEN1
SCHEMBL28165571 0.85 IAPP (0.82) IAPPALOX15IGF1RALOX5OR51E2
SCHEMBL9360095 0.85 IAPP (0.87) IAPPALOX15ALOX5OR51E2CYP19A1
SCHEMBL28349297 0.85 IAPP (0.84) IAPPALOX15ALOX5OR51E2CYP19A1
SCHEMBL12601803 0.84 ALOX5 (0.52) IAPPALOX15IGF1RALOX5OR51E2
Tetrahydrodemethoxycurcumin SCHEMBL29565582 0.82 ALOX5 (0.89) ALOX5OR51E2MEN1LMNACYP1A2
Tetrahydrodemethoxycurcumin SCHEMBL4413210 0.82 ALOX5 (0.89) ALOX5OR51E2MEN1LMNACYP1A2
SCHEMBL3217413 0.81 BACE1 (0.53) ALOX5OR51E2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680143-B2 Orally active curcuminoid compounds LAILA PHARMACEUTICALS PVT. LTD. (US) 2014-03-25 US disclosed
US-8680143-B2 Orally active curcuminoid compounds LAILA PHARMACEUTICALS PVT. LTD. (US) 2014-03-25 US disclosed
US-8568802-B2 Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of Curcuma longa LAILA IMPEX (US) 2013-10-29 US disclosed
US-8568802-B2 Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of Curcuma longa LAILA IMPEX (US) 2013-10-29 US disclosed
US-20110112190-A1 ORALLY ACTIVE CURCUMINOID COMPOUNDS LAILA PHARMACEUTICALS PVT. LTD. (IN) 2011-05-12 US disclosed
US-20110112190-A1 ORALLY ACTIVE CURCUMINOID COMPOUNDS LAILA PHARMACEUTICALS PVT. LTD. (IN) 2011-05-12 US disclosed
US-20100168248-A1 PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA LAILA IMPEX (IN) 2010-07-01 US disclosed
US-20100168248-A1 PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA LAILA IMPEX (IN) 2010-07-01 US disclosed
WO-2010004579-A2 ORALLY ACTIVE CURCUMINOID COMPOUNDS LAILA PHARMACEUTICALS PVT. LTD. (IN) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168248-A1 PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA HMOX1, HMOX2, HPD IAPP 4028/4885ALOX15 180/4885IGF1R 4568/4885
US-20110112190-A1 ORALLY ACTIVE CURCUMINOID COMPOUNDS ALOX12, ALOX15, ALOX15B IAPP 2851/4885ALOX15 2/4885IGF1R 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.